A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19

Abstract

Traditional treatments and symptomatic care are still the only options for most patients as no therapeutic drug has been licensed for treating COVID-19 yet. Monoclonal antibodies generated from convalescent patients or humanized mice exposed to SARS-CoV-2 antigens were awarded emergency use authorization. An ongoing phase I, II, and III placebo-controlled trial is testing whether symptomatic adults can be treated safely and effectively. Casirivimab and imdevimab may have a therapeutic benefit in people who were seronegative when they received treatment. An IgG1 (Immunoglobulin G1) with an unaltered Fc region, Bamlanivimab was generated from the convalescent plasma of a COVID-19 patient. Patients with renal impairment, pregnancy, or breastfeeding status are not advised to alter their dosages. SARS-genomic CoV-2's organization is nearly identical to that of SARS-CoV, with the exception of a few genes for accessory proteins.